A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution

用于超高通量生物催化剂进化的通用液滴微流控平台

基本信息

批准号：
10547670
负责人：
Adam R. Abate
金额：
$ 83.78万
依托单位：
FLUID DISCOVERY INC
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-25 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10547670
关键词：
Abate Active Sites Amino Acids Architecture Automobile Driving Biological Biological Assay Biosensing Techniques Biotechnology Cannabinoids Capital Cells Chemicals Collaborations Complex Computational Technique Computer software Contracts Data Development Directed Molecular Evolution Engineering Environment Enzymes Evolution Feedback Funding Future Genetic Engineering Grant Hand Health Human Industrialization Industry Label Laboratories Letters Libraries Liquid substance Manufacturer Name Mass Spectrum Analysis Materials Testing Mediation Metabolic Microfluidics Mission Mutagenesis Mutation Natural Products Nature Organism Pharmacologic Substance Phase Phenotype Plastics Positioning Attribute Price Printing Privatization Production Property Recombinants Reporter Research Route Running Scheme Science Software Design Source Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Structure Synthesis Chemistry Techniques Technology Testing Translating Variant Yarrowia lipolytica base combinatorial commercialization computerized data processing cost cost effective design drug discovery enzyme activity enzyme pathway gene synthesis innovation instrument mutant nanolitre nanolitre scale novel prototype research and development scale up screening success synthetic biology tool trend

项目摘要

Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, remain the dominant tool. The objective of Fluid Discovery is to transform this field by introducing a novel screening paradigm based on precision nanoliter fluid handling; this groundbreaking approach will increase the scale of screens that can be performed by 100x while driving down costs. In addition to a fundamentally new hardware architecture for scalable screening, our approach implements label-free mass spectrometry and computational techniques to enable discovery of unanticipated enzyme activities and enhancements. Fluid Discovery is founded by the inventor of the key technologies and, thus, is in a prime position to advance this space and become a commercial success. This grant will fuel the development of the first alpha prototype that can be run by early access customers, to illustrate the utility of the technology, its appropriateness for industrial research and development, and its maturity for the market; all of which will be necessary to raise private funding for commercial scale up. Our team includes experts in pharmaceutical development (Dr. Prince), commercialization (Dr. Sunkara), and science and technology (Dr. Abate). This team has a demonstrated track record of commercial success, having built companies with current value >$1 billion. Fluid Discovery’s technology will allow engineering campaigns infeasible with today’s technology at a price point accessible to biotech startups and academic research labs, and with transformative efficiencies attractive to Big Pharma.

抽象的生物技术的进步取决于通过基因设计的方法快速迭代的方法酶和途径。虽然计算和基因合成技术已经考虑了考虑在过去的几十年中，创新的筛查变体已落后，很少有著名的进步。确实，一种近60年历史的技术，Microwell板仍然是主要工具。目标流体发现是通过基于精度引入新颖的筛选范式来改变这一领域的纳米液液体处理；这种开创性的方法将增加可以执行的屏幕规模降低成本时，以100倍的速度为100倍。除了从根本上进行新的硬件体系结构，可扩展筛选，我们的方法实现了无标签的质谱和计算技术以实现发现意外的酶活性和增强功能。流体发现是由库存建立的关键技术，因此处于推动这一空间并成为广告的主要位置成功。这笔赠款将推动可以通过早期访问运行的第一个α原型的开发客户，以说明技术的实用性，其对工业研究的适当性以及开发及其在市场上的成熟度；所有这些都是为了筹集私人资金的必要商业规模。我们的团队包括药品开发专家（Prince博士），商业化（Sunkara博士）和科学技术（Abate博士）。这个团队有一条轨道商业成功的记录，建立了当前价值> 10亿美元的公司。流体发现技术将使当今技术的工程活动不可行，价格可访问生物技术初创公司和学术研究实验室，并具有对大型制药有吸引力的变革效率。